The Lynx Group

Genitourinary Cancers

San Francisco, CA—De-escalating chemotherapy based on a negative positron- emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic seminoma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium.

Read Article

San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision- making process.

Read Article

San Francisco, CA—MicroRNAs have all the characteristics to be a potential game changer as a biomarker in germcell tumors (originating in the testes, ovaries, and a few other sites), with high sensitivity, specificity, and clinical validity in pilot studies, said Lucia Nappi, MD, PhD, Medical Oncologist, British Columbia Cancer, Vancouver Centre, Canada, at the 2020 Genitourinary Cancers Symposium.

Read Article

Orlando, FL—The incidence of bladder cancer is on the rise, and bladder cancer is 4 to 5 times more expensive to treat than breast or prostate cancer. The cost of bladder cancer treatment can be reduced by adhering to the National Comprehensive Cancer Network or the American Urological Association treatment guidelines.
Read Article

Orlando, FL—Clinical trials involving immunotherapy have increased in the past few years, and the oncology community is eagerly awaiting the results. However, not so well-known is what happens to patients who receive immunotherapy outside of the clinical trial setting, including those who are not eligible for clinical trials.
Read Article

Orlando, FL—One cycle of the bleomycin, etoposide, and cisplatin (BEP) regimen had less toxicity and was as effective as 2 cycles in patients with high-risk, nonseminomatous or germ-cell tumors of the testis (NSGCTT), according to results of a large prospective trial called 111 presented at the 2017 Genitourinary Cancers Symposium. Using 1 cycle of BEP as standard of care would reduce exposure to toxicity, and most patients with testicular cancer are relatively young.
Read Article

In the United States, the standard of care for locally advanced bladder cancer after radical cystectomy is to “consider” adjuvant chemotherapy and ad­juvant radiation. Results of a 3-arm randomized clinical trial showed that adjuvant radiation therapy alone or combined with chemotherapy (ie, chemoradiotherapy) did not significantly improve disease-free survival compared with adjuvant chemotherapy alone. However, the findings hint at benefits for chemoradiotherapy that should be studied further. Brian Baumann, MD, a radiation oncology resident at the University of Pennsylvania, Philadelphia, presented the findings at the 2016 Genitourinary Cancers Symposium.
Read Article

High-risk patients with metastatic renal-cell carcinoma (RCC) and venous tumor thrombus derived no benefit from cytoreductive nephrectomy and should be evaluated for clinical trials of systemic therapy, suggested a retrospective multicenter review.
Read Article

Contemporary treatment has led to improvements in survival for all patients with metastatic testicular germ-cell tumors (GCTs), including poor-risk patients, although they still have worse survival. A new study shows that if poor-risk patients receive curative therapy and survive for at least 2 years, their survival approaches that of favorable-risk and intermediate-risk patients. The study supports no further routine scanning 2 years after diagnosis in surviving patients.
Read Article

Cabozantinib (Cabometyx) achieved superior progression-­free survival (PFS) versus standard treatment with everolimus in patients with previously treated advanced renal-cell carcinoma in an updated analysis of the phase 3 METEOR trial, the results of which were reported at the 2016 Genitourinary Cancers Symposium.
Read Article

Page 1 of 2

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: